Paige

About:

Paige builds software to advance the diagnosis, treatment, and biomarker discovery for cancer.

Website: https://www.paige.ai

Twitter/X: paige_ai

Top Investors: Kohlberg Kravis Roberts, Catalio Capital Management, Johnson & Johnson Innovation – JJDC, Breyer Capital, Casdin Capital

Description:

Paige was founded in 2017 by Thomas Fuchs, Dr.Sc., and colleagues from Memorial Sloan Kettering Cancer Center. The Company builds computational pathology products designed so patients and their care teams can make effective, more informed treatment decisions. With this new class of diagnostic devices positioned to drive the future of pathology, Paige created a platform to deliver this novel technology to pathologists to transform their workflow and increase diagnostic confidence and productivity. Paige’s lightweight platform was purpose-built with pathologists to offer an intuitive user experience, and minimize IT burden and costs while ensuring patient safety and data privacy. Paige’s products deliver insights to pathologists so they can arrive efficiently at more precise diagnoses for patients. Paige is the first company to receive FDA breakthrough designation for computational pathology products.

Total Funding Amount:

$220M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

New York, New York, United States

Founded Date:

2018-02-01

Contact Email:

info(AT)paige.ai

Founders:

David Klimstra, Norman Selby, Peter Schüffler, Thomas Fuchs

Number of Employees:

101-250

Last Funding Date:

2021-01-14

IPO Status:

Private

Industries:

© 2025 bioDAO.ai